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Comparative Effectiveness Research in the United States: The Failures And What Can Be Done 
To Fix It 
By: John Barry' 
I. Introduction 
Each year over 750,000 vertebral fractures occur within the United States. 1 The 
preferred treatment for such injuries is vertebroplasty, the injection of acrylic bone cement into 
the affected vertebra.2 Every year Medicare pays for 40,000 of these surgeries, each at a cost of 
$3,000 or more.3 While a common and established procedure, there is actually no evidence that 
vertebroplasy or a number of related spinal procedures provide any benefit to patients above 
what they receive from conservative treatment options such as bed rest or physical therapy.4 
Studies have shown that this surgery is no more effective than "fake," or placebo, surgeries 
performed on those suffering from pain, and in fact, it can create additional risks for patients. 5 
This is but one example of a serious problem within the American medical system: many 
established medical treatments are performed or prescribed based on tradition, rather than 
clinical evidence. 6 This often leads to wasted resources spent on treatments which provide little 
or no benefit. 7 Comparative effectiveness research hopes to solve this problem. 
• J.D. Candidate, 2013, Seton Hall University School of Law; B.A., 2005, University of Pennsylvania. I would like 
to thank Professors John Jacobi and Frank Pasquale for their invaluable guidance and assistance with this comment. 
I would also like to thank my comment editor, Eric Dante, for his patience. 
1 David F. Kallmes et al., A Randomized Trial ofVertebroplasty for Osteoporotic Spinal Fractures, 361 NEW ENG. J. 
MED. 569, 570 (2009); Scott Kinkade & James Stevermer, Vertebroplasty for Osteoporotic Fracture? Think Twice, 
58 J. F AM. PRAC. 654, 654 (2009). 
2 Kallmes, supra note l, at 569. 
3 Robert Langreth, Common Spine Surgery Shows No Benefit, FORBES (Aug. 5, 2009, 05:00PM), 
http://www.forbes.com/2009/08/05/vertebroplasty-healthcare-reform-business-healthcare-backpain.html. 
4 !d. (quoting David Kallmes, the leader of the study, who says "Vertebroplasty as currently practiced in this countty 
and around the world doesn't seem to work"). 
5 !d. (stating that patients who received the surgery had no increased functioning or decreased pain, while at the 
same time had been exposed to increased risks inherent in surgical procedures). 
6 MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE CONGRESS: REFORMING THE DELIVERY SYSTEM (2008), 
available at http:// www.medpac.gov/documents/jun08 _ entirereport.pdf (describing the existence of large gaps in 
evidence between the way in which health care professionals treat patients and what clinical based evidence actually 
shows is effective); see also Jerome Groopman, Why "Quality" Care Is Dangerous, WALL ST. J. (Apr. 8, 2009), 
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Health care costs in the United States are increasing at an exponential rate.8 Total health 
expenditures in the United States have reached 2.5 trillion dollars per year.9 The United States 
surpasses every other country in the world in health care spending per capita.10 However, this 
vast spending has not led to a vastly healthier population. 11 While leading the world in costs, the 
United States ranks 27th in the world for life expectancy of its citizens. 12 This is emblematic of 
the fact that-no matter how hard a country may try to buy its way to health-increased 
spending does not directly correlate to better health outcomes.13 
What is driving these extreme costs with low patient outcomes? While some might claim 
that Americans on a whole are to blame for their poor health, 14 recent studies show that "health 
burdens" that Americans cause themselves account for only a small percentage of total health 
care costs.15 The real answer is that health care costs are a multifaceted problem, with 
http://online.wsj.com/article/SB123914878625199185.html (describing an old adage reportedly told to medical 
students that "[h]alf of what we teach you is wrong- unfortunately we don't know which half'). 
7 See discussion infra Part V. 
8 CTRS. FOR MEDICARE AND MEDICAID SERVS., NAT'L HEALTH EXPENDITURES 20 I 0, available at 
https://www.cms.gov/Nationa!HealthExpendData/downloadslhighlights.pdf. Health care spending rose 3.9% in 
2010, following a 3.8% increase in 2009. !d. 
9 !d. As of the last accounting by the Centers for Medicare and Medicaid Services, this $2.6 trillion has accounted 
for nearly 18% of the gross national product of the United States. !d. 
10 Uwe E. Reinhardt eta!., U.S. Health Care Spending In An International Context, 23 HEALTH AFFAIRS 10, II 
(2004). The United States spends nearly double the funds of the next highest spending country, Switzerland. !d. 
11 !d. 
12 !d. The average life expectancy in the United States is just over seventy seven years of age. !d. at 13. Ranking 
directly behind the United States in 28th place for life expectancy is Cuba, which spends about 3% of what the 
United States spends on health care every year. !d. 
13See Reinhardt, supra note 10. 
14See, e.g., Catharine Paddock, Obesity Healthcare Costs U.S. I 47 Billion Dollars A Year, New Study, MEDICAL 
NEWS TODAY, Jul. 28, 2009, http://www.medicalnewstoday.com/articles/158948.php; Nanci Hellmic, Rising 
Obesity Will Cost U.S. Health Care $344 Billion a Year, USA TODAY, Nov. 17,2011, 
http://www.usatoday.com/news!health!weightloss/2009-ll-17-future-obesity-costs _ N.btm; Patrica McBroom, 
$72. 7 Billion: Smokings Annual Health Care Cost, THE BERKELEY AN, Sept. 16, 1998, 
http:/lherkeley.edu/news/herkeleyan/1998/0916/smoking.html. 
15 Shubham Singhal eta!., How US Health Care Reform will Effect Employee Benefits, MCKINSEY Q, June 2011, 
available at http://www.scribd.com/doc/57371828/McKinsey. This stndy states that while overall Americans are 
more obese than other populations, Americans also consume both less tobacco products and less alcohol then other 
economically developed countries. !d. The disease burden of the unhealthy American lifestyle is pegged at $25 
billion a year, accounting for only 1% of the total cost of health care in the United States. !d. 
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difficulties including availability, delivery, insurance coverage, and more. 16 However, one 
approach that many developed nations have taken is to look closer at the pharmaceuticals and 
medical treatments that drive up health care costs in their systems.17 This Comment will focus 
on comparative effectiveness research, one way in which the United States has chosen to combat 
the rising costs seemingly inherent in pharmaceuticals and medical devices. 
When the Food and Drug Administration (FDA) in the United States approves a drug or 
treatment, the administration does it based solely on the two factors of drug safety and drug 
efficacy. 18 The traditional FDA approval process relies mainly on a comparison of a single 
treatment to a placebo. 19 In contrast, what has gained great favor in many other countries around 
the globe is the use of comparative effectiveness research: the idea of evaluating treatments not 
only to see if they work, but to see if they work better than currently available treatments. 20 
Fortunately, this concept is gaining ground in the United States.21 It holds the potential to have a 
great impact on the American health care system because at the foundation of comparative 
effectiveness research is the concept of providing better, clinically based treatments that in tum 
lead to lower health care costs. 22 
16 U.S. Health Care Costs, KAISER FAMILY FOUND. (2011), available at http://www.kaiseredu.org/lssue-
Modules/US-Health-Care-Costs/Backgrouod-Brief.aspx. 
17 Prescription Drug Costs, KAISER FAMILY FOUND. (20 II), available at http://www.kaiseredu.org/Issue-
Modules/Prescription-Drug-Costs/Background-Brief.aspx ("The rise in costs of prescription medicines affects all 
sectors ofthe health care industry"). 
18 21 C.F.R. § 314.94 (2011). 
19 CATHY SCHOEN ET AL., BENDING THE CURVE: OPTIONS FOR ACHIEVING SAVINGS AND IMPROVING VALUE IN U.S. 
HEALTH SPENDING, THE COMMONWEALTH FUND COMM'N ON A HIGH PERFORMANCE HEALTH SYSTEMS 19-21 
(2007), available at http://www .commonwealthfund.org/Content/Publications/Fund-Reports/2007/Dec/Bending-the-
Curve--Options-for-Achieving -Savings-and-Improving-Value-in-U-S-Health-Spending.aspx 
20 See discussion infra Part Ill. 
21 SCHOEN, supra note 19. 
22 !d. ("Better research leads to better treatments ... which leads to healthier patients ... and in tum a lower 
economic burden on the health care system"). 
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Behind comparative effectiveness research is the idea that "what is newest is not always 
best."23 By systemically comparing medications and medical devices, the hope is to find the 
best, evidenced-based care.24 By finding the most effective clinically backed treatments, health 
care decision makers can treat their patients based on what actually works, without wasting time 
or funds on ineffective treatments. The potential benefit is thus that by knowing the best 
available treatment, care givers can provide better health outcomes, while at the same time save 
money by not wasting resources on ineffective or less effective treatments.25 
Part II of this Comment provides a brief background on comparative effectiveness 
research as it exists within the world of modern medical research. This part also provides a 
background on the history of comparative effectiveness research as used within the United 
States. It focuses on what the Patient Protection and Affordable Care Act,26 the most recent 
overhaul of the American health care system, has authorized this research to be used for, in 
addition to what it may not be used for. Part III then explores the flaws contained in the 
implementation of comparative effectiveness research as it is now currently authorized in the 
United States. This Comment takes the position that as currently implemented, comparative 
effectiveness research will have little effect on either patient outcomes or cost savings in the 
American health care system. The current iteration of this program focuses on providing data 
from comparative effectiveness research to physicians in hopes that they will use the information 
in practice. This Comment takes the position that this use of information from comparative 
effectiveness research will not be effective. 
23 GRETCHEN JACOBSON, CONG. RESEARCH SERV., RL 31340, COMPARATIVE CLINICAL EFFECTIVENESS AND COST-
EFFECTIVENESS RESEARCH: BACKGROUND, HISTORY, AND OVERVIEW I (2007). 
24 !d. 
25 !d. (stating the proposition that ineffective care is costly to the American health care system in many ways. Not 
only are ineffective treatments themselves a waste of funds, the use of ineffective treatments may lead to lower 
health outcomes by depriving patients of more beneficial treatments. Lower health outcomes in tum are costlier due 
to that fact that these patients continue to seek treatment within the health care system). 
26 Patient Protection and Affordable Care Act (PPACA) § 6301 (a), Pub. L. No. 111-148, 124 Stat. 119, 727 (20 I 0). 
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As a foil for what is being implemented in the United States, Part IV analyzes the health 
care system of the United Kingdom. The United Kingdom is among the most prominent leaders 
in implementation of comparative effectiveness research within a health care system. This Part 
will analyze the cost-saving measures within the context of this foreign health care system and 
will explain the benefits and downsides to the system. 
Part V will explore the potential for integrating within the American system lessons 
learned from the United Kingdom. It will discuss the difficulties in creating an effective system 
of better care outcomes and cost savings. Both the social and political climate, which have 
created fears of severe cost cutting and health care rationing, in addition to the potential for real 
problems inherent in the use of comparative effectiveness research, create a difficult atmosphere 
for comparative effectiveness to actually take hold. This Comment proposes that it is possible to 
advance the current implementation of comparative effectiveness research in the United States, 
creating positive health care outcomes and real-world cost savings. However, it should start 
slow and pick the "low hanging fruit" of uncontroversial treatments, specifically avoiding end-
of-life care, so as to gamer acceptance within the patient population, society as a whole, and law 
makers. 
II. Overview of Comparative Effectiveness Research within the United States 
A. Comparative Effectiveness Research as a form of Health Technology Assessment 
Comparative effectiveness research is one branch of a larger tree known as health 
technology assessment (HTA).Z7 HTA is a field of study that looks to measure the value of 
medical technologies such as pharmaceuticals and medical devices in terms of both their medical 
and economic implications.28 It serves to link the world of research-based findings to the world 
27 JACOBSON, supra note 22. at 3. 
28 Id at 4. 
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of clinical, in-practice decision making.29 There are three main branches ofHTA prevalent in 
the world today: comparative effectiveness research, cost-effectiveness analysis, and cost-benefit 
analysis.30 
Comparative effectiveness research, although defined in many different ways, 31 
essentially compares the effectiveness of two or more health care services or treatments?2 It is 
important to note that effectiveness, as defined here, is different from efficacy. Effectiveness is 
the measure of the effect of a treatment in routine clinical practice. 33 In contrast, efficacy, the 
measurement used by the FDA when approving a treatment, is the effect of the treatment under 
optimal conditions?4 By comparing competing treatments in real-world conditions, the hope is 
to find the most effective treatment that leads to the best outcomes for patients. 35 
Cost-benefit analysis and cost-effectiveness analysis are two ways of building upon 
comparative effectiveness research by directly incorporating costs into the assessment of health 
care technologies. 36 These two approaches both compare the cost of services to the additional 
health benefits received. 37 They look to determine whether the additional health benefits, if any, 
serve to justify additional costs?8 Where the two approaches differ is on how the health benefits 
are measured. In cost-benefit analysis, health benefits are valued in monetary terms, and the 
results of each assessment are stated in terms of the monetary difference between treatment costs 
29 !d. 
30 U.S. NATIONAL LIBRARY OF MEDICINE, HTA 101 (2011), available at http://www.nlm.nih.gov/nichsr/hta!Ol/ 
tal0106.html. 
31 See, e.g. COST-EFFECTIVENESS IN HEALTH AND MEDICINE (Martha Gold eta!. eds., 1996); PETER A. UBEL, 
PRICING LIFE: WHY IT'S TIME FOR HEALTH CARE RATIONING (1999). 
32 JACOBSON, supra note 22, at 4. 
33 !d. 
34 !d. at 5. 
35 See SCHOEN, supra note 18. 
36 !d. at 6. 
37 !d. 
38 !d. 
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and health benefits?9 In cost-effectiveness analysis, health benefits are measured in non-
monetary units, with most systems using the unit of life years adjusted for quality, or quality 
adjusted life years (QAL Y).40 What is calculated is a ratio of costs and benefits, a showing of 
the "cost-utility" of the treatment or pharmaceutical.41 QAL Y is seen as, and often criticized for, 
putting a spending cap on people's lives.42 
This Comment will focus on comparative effectiveness research and its potential within 
the American health care system. Further, while other countries are implementing forms of cost-
benefit analysis and cost-effectiveness analysis,43 the social and political climate of America is 
likely not ready for these direct cost-savings measures. 44 And while there may come a time 
when the use of cost-benefit analysis or cost-effectiveness analysis need be further evaluated for 
use in our system, this Comment proposes that comparative effectiveness research is the way to 
gamer greater acceptance for HTA use in every day clinical decision making. 
B. A History of Comparative Effectiveness Research in the United States 
Comparative effectiveness research is not completely new to the United States. The 
earliest government authorization of this form of research began at the state level with Oregon, 
which has used comparative effectiveness in allocating resources to Medicaid recipients.45 Also, 
prior to this, private insurance companies and pharmaceutical manufacturers have used 
39 Id. at 7. 
40 Id; see also infra Part IV. 
41 SCHOEN, supra note 18, at 12. 
42 See infra Part V. The harsh criticism of a QALY -based system will be explored with an examination ofthe 
United Kingdom's health system in this section. 
43 See discussion infra Part V. 
44 See discussion infra Part V; see also John K. Iglehart, The Political Fight Over Comparative Effectiveness 
Research, 29 HEALTH AFF. 1757, 1758 (2010) (stating that comparative effectiveness is seen as akin to cost cutting 
and many Americans feel that it is simply another way for insurers to limit care benefits). 
45 OR. REv. STAT.§ 442.589 (2011); see also Somnath Saha et al., Giving Teeth to Comparative Effectiveness 
Research~ The Oregon Experience, 362 NEW ENG. J. MED. El8(l) (20 l 0), available at 
http:/ /www.nejm.org/doi/pdfll 0 .l 056/NEJMp091293 8. 
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comparative effectiveness research to analyze medications and allocate resources to patients.46 
There has been little oversight of these studies, however, and next to no transparency as to 
research methodologies.47 Thus, these studies are viewed as skewed to the purely economic 
interests of the sponsors rather than towards providing economically efficient care. 48 
On the federal level, the Agency for Healthcare Research and Quality (AHRQ)49 had 
previously been given limited powers to undertake comparative effectiveness efforts. The 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 50 provided a mere 
$15 million per year in funding to AHRQ for research into comparative clinical effectiveness of 
certain health care items and services. 51 Comparative effectiveness research finally gained real 
force in 2009 with the creation of the Federal Coordinating Council for Comparative 
Effectiveness Research. 52 This was a government body created by the massive American 
Recovery and Reinvestment Act of2009,53 a bill which primarily focused on stimulating 
economic activity and job growth in the United States. 54 Over $1 billion was ear marked in the 
legislation to go towards comparative effectiveness research within the United States. 55 
This Federal Coordinating Council was short lived, however, as the sweeping health care 
reform of the Patient Protection and Affordable Care Act (PPACA) created the Patient-Centered 
Outcomes Research Institute (PCORI). 56 PCORI, unlike the Federal Coordinating Council 
46 Steven Pearson, From Better Evidence to Better Care: Using Comparative Effectiveness Research to Guide 
Practice and Policy, in BROOKINGS INST. IMPLEMENTING COMPARATIVE EFFECTIVENESS RESEARCH: PRIORITIES, 
METHODS AND IMPACT 55 (2009). 
47 !d. (explaining that private insurers often operate nnder a veil of secrecy with regards to their savings 
methodologies). 
"!d. at 57. 
49 42 u.s.c. § 299 (2006). 
50 Pub. L. No. 108-173, §1013(e), 117 Stat. 2066, 2438-41(2003)(codified at 42 U.S.C. §299b-7(e)(2006)). 
5l !d. 
52 American Recovery and Reinvestment Act of2009 § 804,42 U.S. C.§ 299b-8 (2010). 
53 American Recovery and Reinvestment Act of2009, Pub. L. 111-5, tit. VII, 123 Stat. 115. 
54 !d. 
55 !d. 
56 Patient Protection and Affordable Care Act (PPACA) § 630l(a), Pub. L. No. 111-148, 124 Stat. 119, 727 (2010). 
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before it, is a non-governmental entity.57 When PPACA becomes effective in 2014, this private 
non-profit organization will largely be comprised of private stakeholders: health care providers, 
pharmaceutical manufacturers, health insurers, and patient representatives. 58 There will also be a 
small number of government officials, such as representative from the National Institutes of 
Health, on the board. 59 
While the Federal Coordinating Council defined the original iteration of comparative 
effectiveness research in use by the federal government, 60 the definition as applicable to this 
Comment comes from PP ACA. PP ACA defines comparative effectiveness research as follows: 
"The term[] 'comparative clinical effectiveness research' ... mean[ s] research evaluating and 
comparing health outcomes and the clinical effectiveness, risks, and benefits oftwo or more 
medical treatments, services, and items."61 These "medical treatments, services, and items" 
include health care interventions, protocols for treatment, care management, and delivery, 
procedures, medical devices, diagnostic tools, pharmaceuticals, integrative health practices, and 
any other strategies or items being used in the treatment, management, and diagnosis of, or 
prevention of illness or injury in, individuals. 62 Though comparative effectiveness research as 
defined by PPACA may be seen as necessarily broad,63 it also raises concerns with some that it 
57 !d. This form of comparative effectiveness research is actually slightly different than was originally proposed. 
The original House of Representatives version of the PPACA provided great strength to comparative effectiveness 
research and what the govermnent was able to do with the data gained. Affordable Health Care for America Act, 
H.R. 3962, lllth Cong. §1401(a)(2009). 
58§ 6301(a). 
59§ 6301(a), § 1181(!), 42 U.S.C. § 1320e(f); see also Press Release, U.S. Gov't Accountability Office, GAO 
Announces Appointments to New Patient-Centered Outcomes Research Institute (PCOR/) Board of Governors, 
(Sept. 23, 2010), available at http://www.gao.gov/press/pcori2010sep23.htrnl. 
6
° FED. COORDINATING COUNCIL FOR COMPARATIVE EFFECTIVENESS RESEARCH, REPORT TO THE PRESIDENT AND 
THE CONGRESS II (2009), available at http:// www.hhs.gov/recovery/prograrns/cer/cerannualrpt.pdf. 
61 PPACA § 6302,42 U.S.C. § 299b-8 (2012). 
62 !d. 
63 Alan M. Garber & Harold C. Sox, Analysis & Commentary: The Role of Costs in Comparative Effectiveness 
Research, 29 HEALTH AFF. 1805, 1805 (20 I 0) (stating the proposition that comparative effectiveness research 
should be defined broadly in order to give PCORI the proper discretion in creating an effective program). 
9 
is simply poorly defined and thus does not give proper structure and guidance for an effective 
clinical comparison system. 64 
III. Comparative Effectiveness Research's Impact in United States 
The main problem with the PP ACA version of comparative effectiveness research, and 
the focus of this Comment, is that the legislation-emphasizes collection of data from comparative 
effectiveness research as the end goal, rather than as a means to achieve cost-effective health 
care options.65 While PPACA established the PCORI and allocates $500 million in funding for 
research,66 it explicitly prohibits PCORI from having any decision-making power in regards to 
"coverage, reimbursement or other policies for any public or private payer."67 Thus, though well 
funded, the PCORI cannot develop practice guidelines, let alone make coverage 
d . . 68 etermmatwns. 
Further, the legislation severely hampers what the Secretary of the Department of Health 
and Human Services may do with the findings ofPCORI.69 Findings may not be used in any 
way that may be construed as valuing the life of the young or non-disabled over the old or 
64 Richard Saver, Health Care Reforms Wild Card: The Uncertain Effectiveness of Comparative Effectiveness 
Research, !59 U. PA. L. REv. 2147, 2161 (2011) ("[l]mprecision creates considerable ambiguity during the critical 
rollout phase of the new legislation. It also enables law makers to avoid, perhaps indefinitely, directly addressing 
hard but critically important policy choices, such as whether comparative effectiveness research should look at 
treatment costs."). 
65 Kevin D. Frick, How Comparative Effectiveness Research Feeds into Cost-Benefit Analysis, 13 AM. MED. Ass'N 
1. ETHICS 248, 249 (20 II) (stating the proposition that collection of data alone from comparative effectiveness 
research is not enough to have a meaningful impact on the health care system). 
66 PPACA § 630l(e), 26 U.S.C. § 9511; see also AM. Ass'N OF MED. COLLS., SUMMARY OF PATIENT-CENTERED 
OUTCOMES RESEARCH PROVISIONS II (201 0). This report contains a summary the PCORI provisions within the 
statute. See id. 
67 PPACA § 630l(a), 26 U.S.C. § 9511. 
68 !d. 
69 CEA Registry Team, NICE Highlights Potential Cost-savings, THE CEA REGISTRY BLOG (May 7, 2010, 4:37PM) 
https:l/research.tufts-nemc.org/cear4/Resources/CEARegistryBlog/tabid/69/ 
Entryld/48/NICE-highlights-potential-cost-savings.aspx (last visited Feb. 9, 2012) ("[L]anguage in the law places 
limitations on the types of evidence that can be used to evaluate health care technologies, hampering the potential to 
create a meaningful 'bending' of the healthcare cost-curve."). 
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terminally ill. 70 While this Comment does not advocate devaluing the life of any person, this 
prohibition may be construed broadly to prohibit much of any cost savings. 71 The statute also 
prohibits the Secretary from making Medicare coverage decisions based "solely" on data from 
comparative effectiveness research. 72 In sum, these restrictions make it extremely hard for 
Medicare and other government health care entities to use the data obtained from comparative 
effectiveness studies in their care and coverage decisions.73 
Today, services and medications are approved for Medicare reimbursement so long as 
they are deemed "reasonable and necessary."74 Medicare does have a provision that allows for 
restricting payment to less costly alternative treatments but it goes unused. 75 At one time, 
Medicare did attempt to use this policy to limit reimbursement of a medication due to existence 
of a less-costly alternative, but it was struck down by the judiciary.76 As such, Medicare has 
since stopped applying this policy when processing reimbursement for drugs covered under 
Medicare's Part B insurance program.77 Further, Medicare has been extremely hesitant to deny 
70 PPACA § 630 I (a}, 26 U.S.C. § 9511 ("[F]indings may not be used in such as manner that treats extending life of 
an elderly, disabled, or terminally ill individual as of lower value than extending the life or an individual who is 
younger, nondisabled or not terminally ill."). 
71 Saver, supra note 63, at 2153 (discussing how this prohibition will likely be a strong deterrence against attempts 
to limit many potentially ineffective care options primarily used by the elderly). 
72 PPACA § 630l(c}, § 1182(b)(2), 42 U.S.C. § 1320e-l(b)(2). 
73 Saver, supra note 63, at 2148 ("[L]awmakers have essentially defanged [comparative effectiveness research], 
deploying it under conditions that will leave it underpowered."). 
74 42 U.S.C. § 1395y(a)(l)(A}-{B). 
75 !d. (Medicare provides reimbursement for treatments only up to the price of their "reasonably feasible and 
medically appropriate" least costly alternatives.); see also MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE 
CONGRESS: ALIGNING INCENTIVES IN MEDICARE 6-7 (2010). 
76 Hays v. Sebelius, 589 F.3d 1279, 1280, 1283 (D.C. Cir. 2009). This cased involved Medicare's denial of 
coverage for a treatment for chronic obstructive pulmonary disease. !d. The court found that Medicare's restriction 
of reimbursement to an inexpensive medication rather than a more expensive alternative was unauthorized by that 
statute. !d. 
77 CMS Instructs Contractors to Rescind All LCA Provisions in Current LCDs, HEALTH POL'Y WKLY 
(AmerisourceBergen Specialty Grp., Wash., D.C.), Apr. 30,2010, https://www.iononline.com/app/Documents/ 
Health%20Policy"/o20 Weekly /20 I 0/ April%203 0,% 2020 I O.pdf. 
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coverage for medications, and even when the FDA has explicitly deemed a medication 
ineffective for treatment of a specific disease, 78 Medicare may still cover it for reimbursement. 79 
Comparative effectiveness research that PP ACA authorizes, in its current form, coupled 
with Medicare's current policies, likely ensures that the money spent to gather data from 
comparative effectiveness research will not save any Medicare funds. 80 It is worthy to note that 
while PCORI is primarily focused on the public payer side, it does show some attention to 
private health plans, but again fails to push any real innovation, as private health insurers have no 
obligation to follow any of the findings ofPCORI and may do with the information as they see 
fit. 81 The private insurers are unlikely to follow the findings ofPCORI without Medicare also 
following suit. 82 
Currently, the end result of the comparative effectiveness program that the PPACA 
authorizes is to make the information available to physicians and hope that they take the 
comparative effectiveness data into account when treating patients. 83 This use of the data faces 
many hurdles, as doctors are unlikely to change their practices of their own accord. 84 First, 
doctors, counter to what wonld commonly be assumed, do not base many of their practices on 
78 Andrew Pollock, FDA Revokes Approval of Avastinfor Use as Breast Cancer Drug, N.Y. TIMES, Nov. 18,2011, 
http://www.nytimes.com/20 11/11/19/husiness/fda-revokes-approva1-of-avastin-as-breast-cancer-drug.html 
79 Andrew Pollock, Medicare Will Pay for Avastin in Treating Breast Cancer, N.Y. TIMES, June 30,2011, 
http://prescriptions.b1ogs.nytimes.com/20 11/06/30/medicare-will-pay-for-avastin-in-treating -breast-cancer/. A vas tin 
was a FDA approved medication for the treatment of breast cancer, but after new evidence came to light that the 
drug was ineffective for this treatment, the FDA removed its approval of the drug for breast cancer treatment. !d. 
Despite new evidence of ineffectiveness and removal of FDA approval, Medicare still agreed to pay for the drug to 
treat breast cancer. !d. The drug will cost Medicare $8,000 per patient, per month of treatment. !d. 
80 Alexander K. Ommaya & Joel Kupersmith, Challenges Facing the US. Patient-Centered Outcomes Research 
Institute, 306 JAMA, 756,756-66 (2011) ("[L]acking a substantial effort focused on implementation, the published 
results of comparative effectiveness research are unlikely to change medical practice on their own."). 
81 PPACA § 6301(a), § 11810), 42 U.S.C. § 1320eG) (2006). 
82 Ommaya, supra note 79, at 757. 
83 Saver, supra note 63, at 2150 (discussing how the information from the research will be made available to health 
care professionals in hopes that they will use it in practice). 
84 Ommaya, supra note 79, at 758 (explaining that physician care practices are extremely hard to change from within 
the physician community itself); see also Saver, supra note 63, at 2150 ("What will be done with the information? 
Not much. Many physicians seem unlikely to change clinical practice patterns, notwithstanding the outcomes of 
[comparative effectiveness research] studies."). 
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data-driven evidence. 85 Access to better evidence relating to clinical practices does not 
necessarily translate into a change in real world practice.86 For example, in 2007, the New 
England Journal of Medicine published the "COURAGE" (Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluation) study. 87 The study showed that heart 
surgery using stents to unclog blocked arteries, a common procedure, was no more effective than 
treating the cardiac patients with drugs alone. 88 As a result of the study, it was thought there 
would be a significant decrease in stent use. 89 However, stent usage has not declined.90 
Secondly, many other factors besides available information or evidence effects the 
decisions that physicians make. Doctors often act based on how they are reimbursed for 
procedures.91 Marketing of pharmaceuticals and treatment options to physicians play a 
significant role in the care given to patients.92 Doctors also respond a great deal to patients' 
requests for specific medications, which is in turn based on advertisements that patients see or 
hear.93 In addition, another important factor driving physician treatment decisions is fear of 
85 See discussion supra note 6. 
86 See William E. Boden, Optimal Medical Therapy With or Without PC! for Stable Coronary Disease, 356 NEW 
ENG. J. MED. 1503 (2007). 
87 /d. 
88 !d. 
89 Keith Winstein, A Simple Health-Care Fix Fizzles Out, WALL ST. J., Feb. II, 2010, available at 
http://online.wsj.com/article/SB I 000142405274870365210457465240 1818092212.html (discussing how stent 
implants "are now back at peak levels" and that such studies "have rarely altered medical practice"). 
90 !d. Part of the reluctance to change may be because physicians (and hospitals) receive better reimbursement for 
performing stent implants than for other treatments. !d. 
91 David Hyman, Follow the Money: Money Matters in Health Care, Just Like in Everything Else, 36 AM. J.L. & 
MED. 370, 381 (2010) ("It is difficult to overstate the extent to which economic incentives explain the structure, 
J;',erformance, and pathologies of the American health care system."). 
ELIZABETH DOCTEUR, How Will Comparative Effectiveness Research Affect the Quality of Health Care?: Timely 
Analysis oflmmediate Health Policy Issues 5-6 (Urban Ins!. 2010); see also MARCIA ANGEL, THE TRUTH ABOUT 
THE DRUG COMPANIES: HOW THEY DECEIVE Us AND WHAT TO DO ABOUT IT, 3-9 (2004) (describing how hundreds 
of millions of dollars are spent bombarding doctors with targeted ads and in office pharmaceutical representatives 
and the tremendous impact this has on the prescribing practices.) 
93 See ANGEL, supra note 90. See also Ezekiel Emanuel, The Perfect Storm ofOverutilization, 299 J. AM. MED. 
Ass. 2789,2790 (2008) (discussing how part of the overutilization of health care can be causally linked to direct-to-
consumer marketing); Thorn Wilder, Despite Doubts About CER's Impact, Studies Should Take Place, Researcher 
Says, 9 MED. REs. L. & POL'Y REP 216 (2010) (Doctors were slow to abandon a traditionally accepted breast cancer 
treatment using a high-dose chemotherapy followed by bone marrow transplants in spite of mounting evidence of 
13 
malpractice liabilities.94 One study involving over-utilization of treatments found a correlation 
between density of attorneys in a given area and the likelihood of over-prescription of 
medications.95 Finally, doctors are hesitant to change their ways, and they value autonomy of 
decision making.96 
These factors coupled together demonstrate that the current state of comparative 
effectiveness research as authorized by the PPACA is likely to accomplish little in the way of 
care outcomes or cost savings. The program as it now exists will spend a great deal of money to 
provide a large amount of valuable data that, without proper implementation, will likely fall on 
deaf ears of health care professionals. 
While comparative effectiveness research as currently implemented in the U.S. will likely 
have little impact, comparative research is being used widely abroad to provide better, more 
efficient care.97 Part IV of this Comment will explore the United Kingdom's use of comparative 
effectiveness. The United Kingdom possesses one of the most established and longest running 
implementations ofHTA. The United States can, and should, use the structuring of this system, 
its benefits, and its downsides to create a more beneficial system in America. 
the treatment's ineffectiveness. This was attributed to patient demand, driven by anecdotal evidence of what patients 
had heard in support groups or from information disseminated from insurance companies.). 
94 Emanuel, supra note 91, at 2790 ("Medical malpractice laws and the resultant defensive medicine also contribute 
to overutilization [of health care]"). 
95 George Sakoulas, Relationship Between Population Density of Attorneys and Prevalence of Methicillin-Resistant 
Staphylococcus Aureus: Is Medical-Legal Pressure on Physicians a Driving Force Behind the Development of 
Antibiotic Resistance?, 16 AM. J. OF THERAPEUTICS I, 6 (Using attorney density in a area as a surrogate for medical 
malpractice likelihood, this study hypothesized that medications, in particular anti-biotics, are over-prescribed by 
p,hysicians out offear that if they fail to prescribe, they run a greater risk of being sued). 
6 Mark Miller, Remarks at the Public Meeting of the Medicare Payment Advisory Commission 107 (Sept. 17, 
2009), available at http://www.medpac.gov/transcripts/0909MedPAC.pdf. A Medicare Payment Advisory 
Commission found that doctors do not like to change practice unless they have to. !d. "Personal experience" with a 
treatment was often enough to make treatment decisions. One physician was quoted as saying "We have our 
judgment, If we like something, if it works, great. !fit doesn't, then we try something else." ld. 
97 See INTERNATIONAL PROFILES OF HEALTH CARE SYSTEMS, THE COMMONWEALTH FUND JUNE 20] 0, available at 
http://www .commonwealthfund.org/Publications/Fund-Reports/20 I 0/Jun/Intemational-Profiles-of-Health-Care-
Systems.aspx (describing comparative effectiveness research system in use in such countries as the United 
Kingdom, France, Italy, Canada, Germany, and Australia). 
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IV. Comparative Effectiveness Research in the United Kingdom 
Statutory authorization for the use of comparative effectiveness research in the approving 
of or paying for medical treatments is not new to Europe and other parts of the world. 98 The 
United Kingdom has a nationalized health care system where all people "ordinarily resident" in 
the country are entitled to predominantly free health care.99 The United Kingdom National 
Health Service (NHS)Ioo established the National Institute for Health and Clinical Excellence 
(NICE) for the purpose of making recommendations for coverage to the NHS in regards to new 
and existing medicines and treatments.IOI The NHS is legally obligated to provide funding for 
pharmaceuticals recommended by the NICE.I02 
The NICE's focus when recommending treatments is not merely on clinical effectiveness 
but also factors in the cost of health care technologies.I03 This model uses a cost-benefit system 
of analysis, I04 relying heavily on cost analysis using quality-adjusted life years (QAL Y).105 
QAL Y is calculated by finding the current quality of life of a patient and examining any increase 
or decrease in quality of life and length of life that a new treatment may offer.I 06 Although each 
drug or treatment is considered on a case-by case basis, generally "if a treatment costs more than 
£20,000 to £30,000 per QAL Y, it will not be considered cost effective."I07 
98 Id. 
99 National Health Service Regulations, 1948, 15 & 16 Geo. 6, § 1483 (Eng.); see also INTERNATIONAL PROFILES OF 
HEALTH CARE SYSTEMS, THE COMMONWEALTH FUND JUNE 20 l 0, available at 
http://www .commonwealthfund.org!Publications/Fund-Reports/20 I 0/Jun/International-Profiles-of-Health-Care-
Systems.aspx 
100 National Health Service, 1999, c. 220 (U.K.). 
101 ld; see also Measuring Effectiveness and Cost effectiveness: the QALY, NAT'L INST. FOR HEALTH AND CLINICAL 
EXCELLENCE, available at http://www.nice.org.uklnewsroom/features/ (last updated Apr. 20, 2010). 
measuringeffectivenessandcosteffectivenesstheqaly.jsp 
102 National Health Service, 1999, c. 220 (U.K.). 
103 International Profiles of Health Care Systems, supra note 95. 
104 See discussion supra Part II. 
105 Id. 
106 Measuring Effectiveness and Cost effectiveness: the QALY, supra note 102. 
101 Id. 
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Many consider the NICE an international role model for the implementation of cost 
effectiveness in health care systems.108 The belief is that the United Kingdom is an innovator, 
taking the steps to curb costs that most other health care systems will be forced to take in the 
future. 109 However, others have harshly criticized the NICE and its drastic use of QAL Y. 110 
Frequently, the NICE has issued guidance restricting the use of new medications that were found 
to be too expensive, based on a QAL Y analysis. 111 The system is criticized as being overly 
formulaic and rigid without allowing for adaptation to the clinical problem at hand.112 Although 
used as a tool for health care systems to battle costs, some cite flaws, such as subjectivity and 
arbitrariness, inherent in a QAL Y -based system. 113 In addition, because the most costly drugs 
are often the ones which are used to treat the sickest patients, the NICE's decisions are further 
thrust into the firing line. For example, the NICE has controversially rejected treatments for 
cancer patients because the costs were deemed too high. 114 Cost-cutting care decisions such as 
these have led to a criticism that the United Kingdom has essentially instituted a system of 
"death panels" which sentence the sick to a lack of care simply due to costs. 115 Thus, the duality 
108 !d. See generally CORINNA SORRENSON ET AL., NICE: HOW DOES IT WORK AND WHAT ARE THE IMPLICATIONS 
FOR THE U.S.? (2008). 
109 Sorrenson, supra note 106. 
110 Paul Eastman, Does NICE have to be Cruel to be Kind?, THE TELEGRAPH, Oct. 30, 2006, 
http://www.telegraph.co.uklhealth/3344366/Does-Nice-have-to-be-cruel-to-be-kind.html; Emma Wilkinson, Talk 
NICE around the Globe, BBC NEWS, Feb. 16, 2009, http://news.bbc.co.uk/2/hilhealth/7830744.stm (discussing how 
a series of controversial treatment denials let to outcry and protest from British citizens). 
111 See MICHAEL SCHLANDER, COMPARATIVE EFFECTIVENESS PROGRAMS: A GLOBAL PERSPECTIVE (GALEN ]NST. 
2009). 
112 !d. 
113 John Wyatt, What"s Wrong with Quality of Life as a Clinical Tool?. 7 AM. MED. Ass'N J. ETHICS 2 (2005) 
(arguing that QAL Y measurements are not as internationally recognized and universally agreed upon as the United 
Kingdom would make them out to be). 
114 Zosia Chustecka, UK NICE Rejects 3 Drugs for Metastatic Colorectal Cancer, MEDSCAPE.COM (Sept. 6, 20 II), 
http://www.medscape.com/viewarticle/749150. Avastin, Erbitux and Vectibix, three medications for colorectal 
cancer, were rejected in 20 II because the cost, upwards of£ 150,000 per QAL Y gained, was deemed too high to 
justify the benefits. !d. Note that these medications are approved for payment by Medicare in the United States. 
!d. 
115 See. e.g., Sophie Borland, The Breast Cancer Patients TOO OLD To Save: Thousands Are Being Denied Surgery 
By 'Ageist" Doctors, THE DAILY MAIL (June 16, 2011, 2:52PM), http://www.dailymail.co.uk/health/article-
2004040/Breast-cancer-Thousands-denied-life-saving -surgery-doctors-base-treatment-age.html#ixzz I kCuTcFir 
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of the comparative effectiveness in the United Kingdom is striking: QAL Y has been used to save 
billions of pounds a year, 116 but the controversy that the QAL Y system has brought with it has 
been great. 117 
V. Reforming Comparative Effectiveness Research in the United States: Meshing 
American Sensibilities with the Need for Change 
As already discussed, the current implementation of comparative effectiveness research 
in the United States will likely produce little impact.118 Development of data is worthless 
without fostering a system that translates evidence into action. 119 However all is not lost. By 
integrating what has been learned from the implementation of comparative effectiveness research 
in the United Kingdom with the needs of the American system, there is room to provide more 
clinically efficient care while still respecting the value of human life. 
While the current implementation of comparative effectiveness research in the United 
States will likely produce little result, the solution is not to directly ration access to 
pharmaceuticals and treatments, as is being done in the United Kingdom, as this is likely not a 
proper fit for America. 120 Limiting access to pharmaceuticals, even minimally, is an extremely 
(stating that 15,000 elderly die prematurely every year because cancer care on the NHS is not as good as that 
provided elsewhere in Europe and the United States); Denis Campbell, Patients Denied Key Treatments Due To· 
NHS Cost-cutting. Surgeons Warn, THE GUARDIAN, Apr. 18,2011, http://www.guardian.co.uk/society/2011/apr/18/ 
nhs-cost-cutting-surgeon-warning (stating that surgeons in the United Kingdom worry that key procedures are 
unfairly being label as having limited clinical value due to cost-cutting measures). 
116 Nicholas Timmons, Letter From Britain: Across The Pond, Giant New Waves Of Health Reform, 29 HEALTH 
AFFAIRS 12 (2010) (estimating that the QALY based system has been used to save the United Kingdom upwards of 
£20 billion a year). 
117 Id. (noting that public protests in the United Kingdom against austerity measures, such as the use ofQALY, are 
not an infrequent occurrence). 
118 See supra Part IV. 
119 Saver, supra note 63, at 2156. 
120 See, e.g., Peter Neumann & Dan Greenberg, Is The United States Ready For QALYs?, 5 Health Affairs 3l("Strict 
adherence to a QAL Y approach is likely to prove unacceptable in the United States."); How the UK Rations Health 
Care, PUBLIC RADIO INTERNATIONAL (Dec. 17,2010, 9:24AM), http://www.pri.org/stories/health/how-the-uk-
rations-health-care.htrnl (stating that rationing, even though controversial in the United Kingdom, would meet an 
exponentially colder reception in the United States. This is premised on the idea that in the United Kingdom 
"rationing [has] become a part of the national identity" due to the history of citizens sacrificing for the nation, 
reaching back to rationing of food and gasoline during World War II). 
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thorny issue in the United States that has already garnered much controversy. 121 There are 
already rampant fears that comparative effectiveness research will lead to "death panels,"122 a 
somewhat Orwellian concept where the ill would be forced to go before tribunals in order to 
have funding approved or denied for their health care. 123 
Even the short-lived Federal Council as established by the ARRA stimulus plan was 
maligned and often mischaracterized. 124 For example, the Wall Street Journal mischaracterized 
the plan as stipulating that certain medications "will no longer be prescribed."125 However, 
much of the fervor today is likely due to a misunderstanding of the complicated legislation or, 
unfortunately, an outright misstatement of what the PCORI is authorized to do.126 Many have 
already confounded the NICE system of the United Kingdom with the legislation as enacted in 
the United States. 127 
121 See, e.g., Alan S. Gerber et al., A National Survey Reveals Public Skepticism About Research-Based Treatment 
Guidelines, 29 HEALTH AFF. 1882 (2010). 
"'Id. 
123 Obama Embraces "Death Panel Concept in Medicare, NEWSMAX (Dec. 26, 2010 6:41PM), 
http://www .newsmax.com/Headline/obama-death-panels-medicare/20 l 01!2/26/id/3 8 I 04 3; Rachel Weiner, P a/in: 
Obama's "Death Panel" Could Kill My Down Syndrome Baby, THE HUFFINGTON POST, May 25, 201 I, 
http://www.huffingtonpost.com/2009/08/07 /palin-obamas-death-panel_ n _ 254399.html (discussing how the once 
presidential hopeful Sarah Palin claimed that PPACA would institute "death panels." Her claim was that those with 
illnesses such as down syndrome would be forced to "stand in front ofObama's 'death panel' so his bureaucrats can 
decide, based on a subjective judgment of their 'level of productivity in society,' whether they are worthy of health 
care. Such a system is downright evil"). 
124 See, e.g., Alicia Mundy, Drug Makers Fight Stimulus Provision, WALL ST. J. (Feb. 10, 2009), 
http:/ /online. wsj .com/article/SB l2342302420396608l.html 
125 !d. But see WSJ Falsely Suggested That Comparative Effectiveness Research Provision in House Bill Dictates 
Certain Treatments "Will No Longer Be Prescribed", MEDIA MATTERS FOR AMERICA, Feb. I I, 2009, 
http://mediamatters.org/research/2009021 10026 (correctly stating that the provision was not a part of the Federal 
Council authorization). 
126 Kativa Patel, Health Reform's Tortuous Route To The Patient-Centered Outcomes Research Institute, 3 I Health 
Affairs 1777, 1778 (stating that media overgeneralizations about PCORJ and comparative effectiveness research 
have led some to distrust the system without actually understanding it). 
127 See David Catron, How Much is a Year of Your Life Worth?, AMERICAN SPECTATOR (July 24, 2009, 6:09AM), 
http://spectator.org/archives/2009/07 /24/how-much-is-a-year-of-your-lif ("This new bureaucracy ... will assign a 
monetary value to your life and deny your care if you contract a malady whose cost-of-treatment exceeds that 
amount.") In reality, the PCORJ is not authorized to take into account QAL Yin any part of the legislation. Martin 
Feldstein, ObamaCare Is All About Rationing, WALL ST. J., Aug. 19, 2009, at AI5 ("rationing health care is central" 
to the new strategy to reduce health care costs). 
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While the talk of"death panels" is vastly over-stated, it must be noted that to properly 
implement a working system of comparative effectiveness research there are valid concerns that 
must be addressed, as a system based on this type of research has the potential to contain great 
flaws. Of foremost importance is the concern that comparative effectiveness research by nature 
cannot adequately take into account individual patient differences. 128 There is also a risk of 
overbroad characterization of certain treatments or medications. 129 Treatments may be defined 
as "the same" when in fact the goals that they serve are different but in a nuanced way. 130 As 
such, an aggressive, rigid system such as that of the United Kingdom is not the best way to 
minimize these problems. What is best is a system which starts out based on conservative use 
comparative clinical effectiveness 131 and then builds on the practical knowledge that is gains 
from real world use. 
In order to assuage public fears and also limit potential complications from a rushed or 
improper implementation of a comparative effectiveness system, this Comment proposes that 
America start slow. For certain types of care, cost effectiveness included in comparative 
effectiveness research may not be the best fit. End-of-life care, while expensive, 132 is the 
128 Saver, supra note 63, at 2155 ("[P]hysicians may rightly be concerned that a particular [comparative 
effectiveness research] study did not include subjects truly representative of their own patients."). 
129 !d. at 2157. 
130 !d. 
131 Miller, supra note 94 (quoting Thomas Dean, Medicare Payment Advisory Commissioner: "We are never going 
to have perfect data. There's always going to be patients who have unique situations, and we have to make sure our 
policies allow for that, and that if we make good clinical decisions that don't entirely follow [the results of 
comparative effectiveness research], there has to be an allowance for that"). 
132 Centers for Medicare and Medicaid Services, Decision Memo for Autologous Cellular Immunotherapy Treatment 
of Metastatic Prostate Cancer, June 30, 2011, available at http://www.cms.gov/medicare-coverage-
database/details/nca-decision-memo.aspx?NCAid~247&veF12&caNarne~ 
Autologous+Cellular+Immunotherapy+ Treatment 
+of+Metastatic+Prostate+Cancer&TimeFrame~? &DocType~All&bc~ AgAA Y AAAIAAA&. Medicare approved 
Provenge, a treatment for prostate cancer that costs $93,000 per patient. !d. See also Courtney Hutchinson, 
Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?, ABC NEWS (July 29, 2010), 
http:/ /abcnews.go.com!Health/ProstateCancerNews/provenge-cancer-vaccine-months-life-worth-I OOk 
/story?id~11269159 (stating that while Provenge has been shown to extend the life of the patient for only four 
months, one reason for the expense of cancer treatments is that because they are traditionally covered by insurance 
and cost effectiveness is not taken into account by insurance companies, drug manufacturers can charge inflated 
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thorniest type of care to address. QAL Y analysis, as has been strictly applied in the United 
Kingdom is not as clear cut as it seems. 133 What constitutes the value or enjoyment of life is the 
subject of countless articles and books. 134 Even ignoring all moral grounds, from simply a 
strategic standpoint, attempting to tackle cost cutting by addressing end-of-life care would only 
give validity to the claims of "death panels" and care rationing that opponents of comparative 
effectiveness research have clamored over.135 This would almost certainly sink the comparative 
effectiveness research ship before it even had a chance to leave port. 
However, end-of-life care is but one portion of growing medical costs. The American 
health care system is ripe with the "low hanging fruit" of routine procedures and medications for 
non-life threatening illness that are not clinically proven but still routinely prescribed. 136 If the 
United States starts by addressing uncontroversial yet costly care, use of comparative 
effectiveness research has a chance of making a foothold in the United States. 
A potential place to start would be by taking a closer look at certain types of "me-too" 
medications. A "me-too" medication is a class of drugs for which there are multiple variants, 
each containing a slightly modified version of the active ingredient. 137 Technically different 
molecules, the production of these medications is an easy way for drug manufacturers acquire 
prices for treatments); Scott Hensley, Debate Over Value ofProvenge Boils over on Medicare Site, NPR (Aug. 8, 
20 1 0), http://www .npr.org/blogs/health/20 I 0/08/02/12893 0253/provenge-medicare-coverage-comments (discussing 
the battle between proponents for providing end-of-life care regardless of cost and those in favor of cutting end-of-
life care that potentially adds little "value" to patients' lives). 
133 See Wyatt, supra note Ill. 
134 See, e.g., COST-EFFECTIVENESS IN HEALTH AND MEDICINE (Martha Gold et al. eds., 1996); PETER A. UBEL, 
PRICING LIFE: WHY IT'S TIME FOR HEALTH CARE RATIONING (1999); JOHN MCKIE, THE ALLOCATION OF HEALTH 
CARE RESOURCES: AN ETHICAL EVALUATION OF THE 'QAL Y' APPROACH (1998); ANDREW EDGAR ET AL., THE 
ETHICAL QAL Y: ETHICAL ISSUES IN HEALTH CARE RESOURCE ALLOCATIONS (1998). 
135 See discussion supra note 120. 
136 See supra notes 2-{); see also Alexandra Kirkley, A Randomized Trial of Arthroscopic Surgery for Osteoarthritis 
of the Knee, 359 NEW ENG. J. 1097 (2005) (finding that arthroscopic knee surgery failed to show any benefit to 
conventional physical therapy); R. Eugene Bailey, Arthroscopic Surgery Ineffective for Osteoarthritis of the Knee, 
51 J. FAM. PRACTICE 10 (2006). 
137 Joshua Gange, How Many "Me-too" Drugs is Too Many?, 305 JAMA 152 (2011). 
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lucrative new patents. 138 For example, proton pump inhibitors (PPis) are a category of drugs 
which are used to treat gastroesophageal reflux disease, commonly known as heartburn. 139 
Nexium, a PPI, is in the top ten of all prescriptions within the United States140 with sales topping 
$8 billion in 2010.141 Nexium shares market space with many other PPis, a group of drugs that 
are generally considered chemically equivalent. 142 "Nexium is no more effective than Prilosec" 
said Sharon Levine, an executive with Kaiser Permanente, the largest health maintenance 
organization in the United States.143 "I'm surprised anyone has ever written a prescription for 
Nexium."144 Nexium can cost over $200 a month, but is the equivalent to Prilosec, a medication 
sold over the counter without need for a prescription. 145 Prilosec costs roughly $15 a month.146 
They are both made by the same company, AstraZenica. 147 
Starting with a small class of drugs, such as "me-too" drugs, and shining a light on the 
inefficiencies inherent in their use, has incredible potential for driving change. Not only will it 
save money directly by moving patients towards use of drugs that are still clinically effective but 
cheaper than others on the market, it has the potential to ease the public and health care providers 
into further acceptance of comparative effectiveness research. Even more, the money that is 
saved may help reduce the burden on the health care system, and thus foreclose the need to make 
138 !d. 
139 Proton Pump Inhibitors, HEARTBURN.COM, http://www.heartburn.com/ReliefAndManagement/PPI.aspx. (last 
visited Feb. 9, 2012). 
140 Twenty Best Selling Drugs, KNOL.COM, http://knol.google.comlklkrishan-maggon/top-ten-twenty-best-selling-
drugs-2010/3fy5eowy8suq3/141# (last visited Feb. 9, 2012). 
141 !d. 
142 Stuart Elliot, Prescription Drug Ads Come Under Criticism, N.Y. TIMES, Oct. 13, 2004, 
http:/ /www.nytimes.com/2004/ I 0/12/business/worldbusiness/12iht-drugs.html. 
143 !d. 
144 !d. 
145 !d. 
146 !d. 
147 Products A-Z, ASTRAZENICA.COM, http://www.astrazeneca.com/Medicines/Products-A-Z (last visited Feb. 10, 
2012). 
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difficult decisions about expensive end-of-life care in the future. This is directly counter to what 
people fear will happen with "death panels." 
This slow and easy start to using comparative effectiveness research in the United States 
further holds the potential to not only drive down health care costs but also to drive greater 
innovation. It is extremely expensive to produce innovative drugs, but much cheaper to produce 
"me-too" drugs. 148 In 2004, 75% of the drugs that the FDA approved were classified as similar 
to existing ones on the market in either chemical makeup or therapeutic value.149 Marcia Angell, 
former editor-in-chief of the New England Journal of Medicine, stated that "over the past two 
decades [the drug industry] has moved very far from its original pnrpose of discovering and 
producing useful new drugs."150 She claims that the pharmaceutical companies are now 
"primarily ... marketing machine(s) that sells drugs of dubious benefit. 151 By being able to 
produce profitable "me-too" medications, pharmaceutical companies have less incentive to 
invest in research and development for novel and potentially more needed drugs. 152 
The FDA cannot take into account cost effectiveness when approving drugs to market.153 
With Medicare and PCORI hamstrung by legislation from effectively taking into account cost 
effectiveness or relative therapeutic value of drugs, pharmaceutical companies have little 
incentive not to spend money on marketing campaigns for recycled drugs rather than striving for 
148 Rosesanne Spector, Me-Too Drugs: Sometimes They Are Just The Same Old, Same Old, STANFORD MED. MAG. 
Summer 2005, available at http://stanmed.stanford.edu/2005summer/drugs-metoo.html. 
149 !d. 
150 See ANGEL, supra note 90. 
151 Jake Whitney, Pharmaceutical Sales 101: Me-Too Drugs, GUERNlCA MAG, Feb. 2006, available at 
http://www.guernicamag.com/featureslllllme _too_ drugs/ (discussing how many physicians and academics feel that 
pharmaceuticals have a tendency to look towards easy profits, not innovation. "Overall, the top U.S. pharmaceutical 
companies spend between two and two-and-a-halftimes as much on 'marketing and administration' as they do on 
research and development"). 
152 AIDAN HOLLIS, Me-Too Drugs: Is There A Problem? (World Health Org. 2004), available at 
http://www.who.int/intellectualproperty/topics/ip/Me-tooDrugs_Hollisl.pdf("The key problem with me-too drugs is 
that, to the extent that they are similar to pre-existing drugs, they diminish the incentives for innovation in 
pioneering drugs without adding therapeutic value. Me-too drugs also absorb [research and development] resources, 
which is wasteful if they are undifferentiated from pre-existing drugs"). 
153 21 C.F.R. § 314.94. 
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new innovative treatments. 154 This Comment does not argue that the FDA should ban safe and 
effective drugs from authorization in the United States simply because they might not be cost-
effective.155 However, by having Medicare, the largest insurance payer in the United States, look 
closely at the relative clinical effectiveness of medications, drug manufacturers will maintain 
incentives to spend their funds on new drug innovation. By moving manufacturers away from 
recycling drugs with new patents, the benefits for approving a new drug for payment in the same 
medication class become less and less.156 
By having Medicare take into account comparative clinical effectiveness, an added 
incentive is that it will not only legitimize the practice for additional use by private insurance 
companies, it will actually push them to use it. Medicare makes decisions that "profoundly 
affect ... the cost-benefit calculations and policy decisions of ... [private] insurers."157 
Medicare provides health coverage to one out of every seven Americans. 158 Its reimbursement 
and coverage policies are widely adopted by private insurers and other public programs. 159 Since 
private insurers are driven by Medicare as the first mover, mandating that for certain procedures 
or medications Medicare must take into account cost effectiveness will push the private side to 
do the same. 160 
154 Gange, supra note 132 (discussing how different variations of the same stalin class have been patented over a 25-
year period with little showing of difference in effectiveness for patient populations). 
155 Scott Hensley, Should FDA Hold 'Me-Too' Drugs To A Higher Standard?, NPRHEALTH BLOG (Feb. 15, 2011), 
http://www .npr.orglblogs/health/20 11102/17/13 3 784085/should-fda-hold-me-too-drugs-to-a-higher-standard. 
156 See Gange, supra note 132. 
157 RlCK MAYES, MEDICARE PROSPECTIVE PAYMENT AND THE SHAPING OF U.S. HEALTH CARE (2006). 
158 /d. 
159 Center On Budget and Policy Priority Decisions, Medicare Changes Can Complement Health Reform (July 31, 
2008), http://www .cbpp.org!cms/index.cfin?fa~view&id~563. 
160 OFFICE OF TECHNOLOGY ASSESSMENT, US CONGRESS, MEDICAL TECHNOLOGY AND COSTS OF THE MEDICARE 
PROGRAM (1984). 
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VII. Conclusion 
"No publically funded health care system ... can possibly pay for every new medical 
treatment ... choices have to be made."161 While it may be somewhat unsettling to envision a 
system where health care choices are made with view towards economy, this statement bluntly 
describes the realities that health care systems, both public and private, face in countries across 
the globe. With health care costs rising every year, 162 something must be done to curb spending. 
Comparative effectiveness research is unique in that it holds the promise of cutting costs 
while actually increasing health outcomes. 163 While some countries like the United Kingdom 
have used comparative effectiveness to ration care, 164 comparative effectiveness research is more 
accurately framed in a different light. At its foundation is not the rationing of care, but actually 
the providing of better care. 165 The best promise for comparative effectiveness research to make 
a difference in America is to use it to weed out expensive, redundant, or unfruitful treatments so 
patients can get the right treatment. Cost effectiveness is an added benefit to, and inherently 
flows from, providing proper, effective treatments to patients. If you provide people with the 
proper care, not just the newest or most expensive care, people will be healthier, use less of the 
resources ofthe health care system, and in tum the system will save money. 
Although comparative effectiveness research has been maligned due to fear of care 
rationing and "death panels,"166 if the United States implements the system the right way, it can 
foster a better understanding of what comparative effectiveness research actually means. 
161 Measuring Effectiveness and Cost effectiveness: the QALY, supra note 102. 
162 US. Health Care Costs, KAISER FAMILY FOUND. (20 II), http://www.kaiseredu.org/Issue-Modules/US-Health-
Care-Costs/Background-Brief.aspx (citing that health care costs in the United States have risen every year and total 
costs tripled between 1990 and 1998). 
163 Saver, supra note 63, at 2147 ("If [comparative effectiveness research] works as planned, it may be one of the 
few reform measures in the final health care legislation that could flatten the cost curve while also improving 
quality"). 
164 See discussion supra Part V. 
165 See discussion supra Part V. 
166 See text accompanying supra notes 106, 109. 
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Garnering doctor, patient, and political support for this system is essential if a difference is to be 
made in the health care system. While comparative effectiveness research carries with it very 
real potential downsides, if implemented with an eye towards caution, these downsides can be 
avoided. 167 
Thus, the translation of research data to clinical outcomes should start slowly. 
Treatments that involve end-of-life care or lifesaving procedures are undoubtedly expensive, but 
starting a comparative effectiveness program that attacks this end of the health care cost 
spectrum is unwise. There is much to be saved on the other end ofthe spectrum, by starting to 
take action with routine, everyday medications and procedures. By starting with low-level 
medications that treat non-life threatening illnesses, we can make a smart, sensible change in the 
way medications and treatments are prescribed. This will garner support for comparative 
effectiveness research, lower health care cost, drive pharmaceutical innovation and create a 
healthier populace. 
167 See discussion supra Part VI. 
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